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Abstract
Background: Dysregulations in alternative splicing (AS) patterns have been associated with many human diseases
including cancer. In the present study, alterations to the global RNA splicing landscape of cellular genes were
investigated in a large-scale screen from 377 liver tissue samples using high-throughput RNA sequencing data.
Results: Our study identifies modifications in the AS patterns of transcripts encoded by more than 2500 genes
such as tumor suppressor genes, transcription factors, and kinases. These findings provide insights into the
molecular differences between various types of hepatocellular carcinoma (HCC). Our analysis allowed the
identification of 761 unique transcripts for which AS is misregulated in HBV-associated HCC, while 68 are unique to
HCV-associated HCC, 54 to HBV&HCV-associated HCC, and 299 to virus-free HCC. Moreover, we demonstrate that
the expression pattern of the RNA splicing factor hnRNPC in HCC tissues significantly correlates with patient
survival. We also show that the expression of the HBx protein from HBV leads to modifications in the AS profiles of
cellular genes. Finally, using RNA interference and a reverse transcription-PCR screening platform, we examined the
implications of cellular proteins involved in the splicing of transcripts involved in apoptosis and demonstrate the
potential contribution of these proteins in AS control.
Conclusions: This study provides the first comprehensive portrait of global changes in the RNA splicing signatures
that occur in hepatocellular carcinoma. Moreover, these data allowed us to identify unique signatures of genes for
which AS is misregulated in the different types of HCC.
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Background
Hepatocellular carcinoma (HCC) represents the fifth
most prevalent tumor type and the third leading cause
of cancer-related deaths around the world [1]. Chronic
infection with hepatitis B virus (HBV) and hepatitis C
virus (HCV) are the major causes of HCC worldwide
[2]. These two hepatotropic viruses represent the most
important risk factors for the development of HCC, with
an estimated 80 % of all HCC cases globally [3].
HBV and HCV induce carcinogenesis via different mo-
lecular mechanisms. HBV infection causes HCC via both
indirect and direct pathways [4]. HBV infection promotes
chronic injury to liver cells, with constant necro-
inflammation and regeneration activity [5]. As a conse-
quence, an increase in hepatocyte turnover is observed
which leads to the accumulation of potential critical muta-
tions with subsequent malignant transformation and
clonal expansion, leading to HCC [6]. Moreover, HBV in-
fection can directly lead to HCC by integrating the viral
genomic DNA into the host genome [7]. HBV integration
can lead to numerous mutagenic consequences, including
deletions, translocation, large inverted duplications, and
amplifications, resulting in chromosomal instability [8]. In
contrast, HCV does not integrate into the hepatocyte gen-
ome. The central hypothesis for HCV carcinogenesis is
that it occurs via indirect pathways through chronic in-
flammation and hepatocellular injury. This is supported
by the fact that cirrhosis is frequently a pre-requisite for
HCV-induced HCC [4]. However, HCC has been reported
to develop in a very small proportion of non-cirrhotic pa-
tients, suggesting a more direct effect from HCV itself [9].
Accordingly, various HCV proteins have been shown to
have a role in the development of HCC development in
various experimental models [10].
Alterations in RNA splicing of a small number of cel-
lular genes have been observed in HCC, and although
still limited, the available data suggest that splicing
defects may play a role in hepatocarcinogenesis [11].
Higher eukaryotes use alternative splicing (AS) to
change the composition of transcripts encoded by a gene
through selection of different exons to be included in
the mature mRNA, thus producing a variability at the
proteomic level [12]. AS therefore diversifies the cellular
proteome because it results in multiple transcripts and,
as a consequence, various proteins are created from a
single gene. These different proteins produced from the
same gene can frequently promote different or even
opposite biological effects. As a result, the relative abun-
dance of each isoform may have consequences on cellu-
lar functions. An example of this is clearly demonstrated
by the BCL-x gene. AS of the Bcl-x transcript results in
two different mature mRNAs: Bcl-x(L), which has anti-
apoptotic effects, and Bcl-x(S) which promotes apoptosis
[13]. Therefore, it is not surprising that AS is tightly
regulated and that variations in splicing patterns have
been associated with many human diseases including
cancer [14]. During the last few years, cancer-specific
splice variants and cancer-associated changes in the rela-
tive levels of spliced isoforms of genes with a recognized
role in carcinogenesis have been observed [15]. AS alter-
ations can confer selective advantages to tumors, such as
angiogenesis, proliferation, cell invasion and avoidance
of apoptosis [16]. Recent evidences indicate that some of
these can be used as prognostic or diagnostic bio-
markers, and the development of strategies to correct
and/or inhibit pathological splicing events will be key in
order to develop future therapeutic approaches [17].
Various studies have shown alterations in the AS pat-
terns of a limited number of cellular genes in HCC [11].
One interesting case of dysregulated AS occurring in
HCC is the overexpression of a splice variant of DNA
methyltransferase 3b (DNMT3b), namely DNMT3b4
[18]. An elevation of the ratio of DNMT3b4 to
DNMT3b3 mRNA is correlated with DNA hypomethyla-
tion on pericentromeric satellite regions which may in-
duce chromosomal instability and is considered an early
event during hepatocarcinogenesis [18]. Other examples
of aberrantly-spliced genes detected in HCC include the
serine/threonine kinase aurora kinase B (AURKB), the
E3 ubiquitin ligase, the p53-antagonistic protein MDM2,
the cell surface adhesion cadherin 17 protein, and the
Hugl-1, Klf6, and p73 tumor suppressors [11]. These ex-
amples illustrate the oncogenic potential of aberrantly
spliced isoforms in HCC tissues.
In the present study, alterations to the global cellular
AS landscape of more than 377 liver tissue samples from
The Cancer Genome Atlas (TCGA) were investigated
using high-throughput RNA sequencing data. This study
provides a comprehensive portrait of global changes in
the RNA splicing signatures that occur in HCC. We
identify modifications in the AS patterns of transcripts
encoded by more than 2500 genes such as transcription
factors, tumor suppressor genes, kinases, and splicing
factors. These findings allowed the identification of
unique gene signatures for which AS is misregulated in
different types of HCC.
Results
Modification of the cellular AS landscape in HCC
Alterations to the global RNA splicing landscape of
more than 377 liver tissue samples (Fig. 1a) from The
Cancer Genome Atlas (TCGA) were investigated using
high-throughput RNA sequencing data. The overview of
all the analyses performed in this study is outlined in
Fig. 1b. RNA-seq data were collected and mapped to the
reference genome, followed by transcript assembly and
analysis of RNA isoform abundance. We initially focused
our study on HBV-associated HCC (THBV, Tumors with
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HBV) and HCV-associated HCC (THCV, Tumors with
HCV), and we compared the global splicing patterns
with normal tissues (NNoV, Normal, no virus). In order
to identify the cellular AS patterns that are altered in
HCC, we evaluated the modifications in splice abun-
dances by quantifying all the primary transcripts that
generate two or more isoforms. Alternative splicing
events (ASEs) were detected and quantified using the
percent-spliced-in (PSI) metric based on isoform expres-
sion (transcript-per-million, TPM) for the long and the
short isoforms (see Experimental Procedures). The lists
of ASEs (42,000–45,000 ASEs) were filtered to keep only
data with at least two replicates for both types of HCC
and normal hepatic tissue. The ASEs that differed be-
tween HCC tissues and normal hepatic tissue with a P-
value of less than 0.05 were conserved. To ensure higher
stringency, the ASEs were further filtered with a cutoff
Q-value (false-discovery rate) of less than 0.05. From
these events, only those with a difference higher than
10 % in |Delta PSI| were considered biologically relevant.
Using such an approach, we identified 3250 primary
transcripts belonging to 2051 genes for which the AS
pattern was significantly modified in patients with HBV-
associated HCC (Q ≤0.05, |Delta PSI| ≥10) (Fig. 1c).
Moreover, the AS patterns of 1380 primary transcripts
belonging to 907 genes were significantly modified in pa-
tients with HCV-associated HCC. The complete list of
the differential ASEs associated with HBV- and HCV-
associated HCC is provided in Additional file 1. The list
includes six of the previously identified aberrantly
spliced isoforms found in HCC in previous studies
(DNMT3b, AURKB, UBE3B, MDM2, KLF6, and TP73).
RNA-Seq data were not available for the two other
previously identified examples of aberrantly-spliced
genes detected in HCC (CDH17 and HUGL1).
Our analysis revealed that the expression of a vast
number of cellular transcripts was modified in patients
with HBV- and HCV-associated HCCs as compared to
normal healthy tissues (Fig. 2a–b). In the case of HBV-
associated HCC, 361 transcripts had |Delta PSI| values
higher than 30 % (Additional file 1: Figure S1A), while
200 transcripts had |Delta PSI| values greater than 30 %
for HCV-associated HCC. To identify cellular pathways
for the differential ASEs associated with HBV- and
HCV-associated HCC, we performed a functional en-
richment analysis of the genes for which AS is modified.
In both cases, the analysis revealed significantly enriched
(Q ≤0.05) terms in both metabolic process (28.6 and
27.4 % for HBV- and HCV-associated HCC, respectively)
and developmental process (6.6 and 7.1 % for HBV- and
HCV-associated HCC, respectively) (Additional file 1:
Figure S2A). Indeed, a significant number of the modi-
fied ASEs are encoded by genes with important roles in
metabolism. For instance, alterations in the splicing pat-
terns of BCAT2, which encodes a branched chain ami-
notransferase found in mitochondria, DAP3, which
helps in protein synthesis within the mitochondrion, and
ECHDC2, which is involved in fatty acid biosynthesis,
were found to be present both in HBV- and HCV-
associated HCC. A large number of these proteins ap-
pear to interact either directly or indirectly with each
other (Additional file 1: Figure S2B). Through manual
curation of functional annotations, we also identified
numerous modifications in the AS patterns of genes po-
tentially involved in oncogenic transformation. We iden-
tified many transcription factors, receptors, tumor
B
Fig. 1 Alternative splicing of HBV- and HCV-associated hepatocellular carcinoma. a Classification of the TCGA RNA sequencing data for HCC and
healthy tissues. b Overview of the strategy used to identify the changes in splicing for each type of HCC. c The splicing events list for HBV-
associated HCC (THBV/NNoV) and HCV-associated HCC (THCV/NNoV) was filtered to keep only significant ASEs
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suppressors, and kinases for which AS is significantly modi-
fied in HBV- and HCV-associated HCC (Additional file 1:
Table S1). For example, HBV-associated HCC displayed al-
terations in the AS patterns of 138 tumor suppressors, 156
transcription factors, 73 kinases, and 132 receptors. Some
of the dysregulated ASEs that were identified include
KRAS, a member of the small GTPase superfamily impli-
cated in various pathologies (such as lung adenocarcinoma,
pancreatic cancer and colorectal carcinoma), MDM2, a
nuclear-localized E3 ubiquitin ligase which can promote
tumor formation by targeting tumor suppressor proteins
(such as p53) for proteasomal degradation, and BRCA1
which encodes a nuclear phosphoprotein that plays a role
in maintaining genomic stability, also acts as a tumor sup-
pressor and is frequently mutated in breast and ovarian
cancers. Interestingly, some of these modifications are
found both in HBV- and HCV-associated HCC while
others are unique to the respective virus-associated HCC
(Fig. 3a–b and Additional file 1: Figure S3A–B). It should
be noted that we found no evidence for correlation between
the presence of one or more splice variants and clinical pa-
rameters (such as patient survival).
Fig. 2 Global profiling of alternative splicing event modifications in HBV- and HCV-associated HCC. a Alternative splicing event modifications in
HBV-associated HCC (THBV/NNoV) and HCV-associated HCC (THCV/NNoV) are presented with their associated changes in gene expression. The
graphs represent the relation between the difference of splicing for each hepatitis-associated HCC compared with healthy non-viral tissues, and
the difference in gene expression for each of these alternative splicing event modifications. b Heatmap representations of isoform ratios (PSI values) for all
tissues analyzed in the current study. The first heat map shows PSI values for HBV-associated HCC. HBV-associated HCC tissues (THBV) are shown in red,
and the comparative healthy tissues are shown in green (NNoV). The second heat map shows PSI values for HCV-associated HCC. HCV-associated HCC
tissues (THCV) are shown in blue, and the comparative healthy tissues are shown in green (NNoV)
Fig. 3 AS modifications in transcripts encoded by tumor suppressors and oncogenes in HBV- and HCV-associated HCC. a Alterations in the AS
patterns of transcripts encoded by tumor suppressors in HBV- and HCV-associated HCC. Some transcripts have multiple ASEs that are modified.
Red bars indicate negative Delta PSI values, and blue bars represent positive Delta PSI values. b Alterations in the AS patterns of transcripts
encoded by oncogenes in HBV- and HCV-associated HCC. The tumor suppressors and oncogenes were selected based on the TSGene
[64] and allOnco databases (http://www.bushmanlab.org/links/genelists)
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Characterization of the ASEs that are modified in HCC
We next compared the profiles of the ASEs that are al-
tered in HBV- and HCV-associated HCC. The vast major-
ity of the ASEs that are modified in HCC were found at a
level of one splicing event per gene (Additional file 1:
Figure S1B). Analysis of the correlation between AS and
gene expression indicated stable expression of most of the
transcripts that are differentially spliced (Fig. 2a). Overall,
we observed no clear association between the expression
level and the cancer-specific splicing pattern, demonstrat-
ing that there is no relationship between the regulation of
transcription and the control of alternative splicing in
these cancer-specific genes.
Among the transcripts for which AS was significantly af-
fected in HBV- and HCV-associated HCC, many ASEs we
documented affect known protein domains. Additional
file 1: Table S2 displays the consequences of the differen-
tially spliced transcripts on protein function for 60 tran-
scripts that are differentially spliced in HCC. Among the
differential ASEs, at least two ASEs resulted in the loss of
predicted nuclear localization signals (NLS). These are
RINT1, which plays a role in cell cycle checkpoint control
and is essential for telomere length control, and EHD3, a
paralog of EHD1, a protein which is thought to play a role
in the endocytosis of IGF1 receptors. Twenty other ASEs
were predicted to disrupt known functionally critical
protein domains. Most of these genes encode for proteins
involved in metabolic processes. For instance, some of
the dysregulated ASEs lead to protein domain loss in
HADHA. This gene encodes the alpha subunit of the
mitochondrial trifunctional protein, an enzyme which
catalyzes the final three steps of mitochondrial beta-
oxidation of long chain fatty acids, and ALDH2, the
second enzyme of the major oxidative pathway of al-
cohol metabolism.
Experimental validation on HCC tissues
We next sought to experimentally validate the results that
were obtained from the RNA-Seq data. We used PCR ana-
lysis to experimentally validate the differential ASEs that
were observed through RNA-seq studies. Using liver
cDNA arrays from both healthy and cancerous tissues, we
designed specific primers to allow detection of the various
ASEs by PCR. Examples of differentially spliced transcripts
are presented in Fig. 4a illustrating the modifications in
isoform usage in transcripts encoded by three different
genes (OSBPL6, VPS13A, ZNF692). In all three cases, the
experimental Delta PSI values were similar to the values
obtained from RNA-Seq analysis (Fig. 4b). The experi-
mental Delta PSI values ranged from −17.9 (for the
VPS13A transcript) to 15.6 (for the ZNF692 transcript).
Overall, our results demonstrated that changes in AS
levels revealed through transcriptome sequencing could
also be detected by PCR analysis (Fig. 4b).
Comparison between different types of HCC
The large size of the samples analyzed by high-
throughput RNA sequencing allowed us to obtain data
for the alterations to the global RNA splicing landscape
of two other types of HCC, namely HCC associated with
the co-presence of both HBV and HCV (THBV&HCV)
and virus-free HCC (TNoV, Tumor no virus). Because of
their shared modes of transmission, co-infection of HBV
and HCV is not uncommon, particularly in countries
with a high prevalence of HBV or HCV [19]. HBV and
HCV co-infection results in more severe liver patholo-
gies and in an enlarged risk of HCC than monoinfection
[19]. While the number of HCC tissues associated with
the presence of both HBV/HCV was relatively small in
our samples collection (n = 3), our statistical analysis
allowed us to identify 220 transcripts for which AS is
modified in comparison to normal tissues (Additional
file 1: Figures S1C, S4A, Tables S3–S6). Remarkably, 79
genes for which AS was modified were found to be com-
mon between the three types of virus-associated HCC
(Fig. 5a). This raised the possibility that these common
ASEs might be related to a general characteristic of can-
cerous tissues. We therefore analyzed the cellular AS
patterns that are altered in virus-free HCC of 131 pa-
tients (TNoV; tumor, no virus), and we evaluated the
changes in relative splice abundances. Using such an
approach, we identified 1517 genes for which the AS
pattern was significantly modified in virus-free HCC
(Q ≤0.05, |Delta PSI| ≥10) (Additional file 1: Figures S1C,
S4B, Tables S3-S6). Further analysis revealed that 75 of the
79 previously identified genes for which AS was modified
in the three types of virus-associated HCC were also iden-
tified in virus-free HCC, thereby indicating that the modi-
fications in AS found in those genes are associated with
carcinogenic tissues. It should be noted that the AS of the
four remaining genes were also found to be modified in
virus-free HCC although they were not retained following
the statistical analysis i.e. the Q-values were slightly higher
than 0.05 and/or the |Delta PSI| were slightly lower
than 10. Overall, our analysis allowed us to identify
761 unique transcripts for which AS is misregulated
in HBV-associated HCC, while 68 are specific to
HCV-associated HCC, 54 to HBV&HCV-associated
HCC, and 299 to virus-free HCC (Fig. 5b, Additional
file 1: Tables S7–S11).
Expression levels and AS of RNA splicing factors
The precise mechanism which leads to a modification of
the AS landscape in HCC is unknown at the moment.
Changes in splice site choice generally arise from varia-
tions in the assembly of the spliceosome or by altering
the binding of splicing factors to the RNA transcripts
[20]. Although splicing is controlled by a large set of
splicing factors, dysregulated expression of individual
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splicing factors has been shown to frequently result in
aberrant splicing [21]. Taking these findings into consid-
eration, we thus monitored both the expression levels
and the changes in splicing patterns of RNA encoding
for splicing factors and spliceosomal proteins. As shown
in Fig. 6a, the expression of some splicing factors and
spliceosomal proteins is indeed affected in HCC. The
expression of 94 proteins involved in splicing was modu-
lated by more than 2-fold in HBV-associated HCC.
Interestingly, the expression of ESRP1, a splicing factor
known to regulate diverse types of alternative splicing
events [22], was increased by more than 21-fold in HBV-
associated HCC. Very similar expression profiles were
also found in HCV-, HBV&HCV-associated HCC and
B
Fig. 4 Validation of ASEs dysregulated in HCC. a Overview of the two isoforms encoded by OSBPL6, VPS13A and ZNF692 genes. Exons are
depicted in red and the intervening introns are shown as thin black lines (not to scale). The primers used to detect the isoforms by RT-PCR assays
are shown in gray and the sizes of the expected amplicons are also indicated. b cDNA obtained from tissues were analyzed by PCR using specific
primers to detect both isoforms of the transcripts encoded by the OSBPL6, VPS13A and ZNF692 genes. Capillary electrophoregrams of the PCR
reactions are shown. The positions and the amplitude of the detected amplicons are highlighted by red boxes. The positions of the internal
markers are also indicated. The Delta PSI values for both the RNA-Seq and experimental validation assays are shown on the right
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Fig. 5 Comparison between HBV-, HCV-, HBV&HCV-, and non-viral-associated HCC. a The list displays the common differentially spliced transcripts
for the various types of HCC with the corresponding Delta PSI values, the associated gene expression (in Log2), and the associated biological
processes. b Comparison of the genes with dysregulated ASEs between HBV-, HCV-, HBV&HCV-, and virus-free HCC
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virus-free HCC (Additional file 1: Figure S5). Immuno-
nohistochemical staining confirmed the over-expression
of various splicing factors in HCC tissues, as compared
to normal liver tissues, including ESRP1, CWC27, and
DDX41 (Fig. 6b).
Modifications to the AS patterns of transcripts encoding
proteins involved in splicing (splicing factors and proteins
of the spliceosome) was also investigated. Our study identi-
fied many splicing factors that were differentially spliced
upon in HCC (Fig. 6c). In the case of HBV-associated
HCC, the AS patterns of 26 splicing factors were signifi-
cantly modified. One example is RBFOX2, which encodes
an RNA-binding protein that is thought to be a key regula-
tor of alternative exon splicing. Other examples include
CELF2, which regulates pre-mRNA alternative splicing and
may also be involved in mRNA editing, and translation,
and MBNL1, which can also regulate splicing on specific
pre-mRNA targets. Modifications to both the expression
level and AS of splicing factors likely contribute to the ob-
served changes in the cellular AS landscape of HCC.
B
Fig. 6 RNA splicing factors in HCC. a Iris Graph representing the expression profile of splicing factors for HBV-associated HCC. Differences in gene
expression levels are shown on a logarithmic color scale (Log2), from red (negative changes in expression) to blue (increase in gene expression).
b Expression of splicing factors in both normal liver tissues and hepatocellular carcinomas. These images were extracted from the Human Protein
Atlas database, according to its academic usage permission (see Ref. [65] and www.proteinatlas.org). The images show the results of immunohis-
tochemical staining using specific antibodies (complete list and experimental protocol found at www.proteinatlas.org), followed by detection with
horseradish peroxidase. Immunohistochemical staining was performed on both normal and HCC tissues for three different splicing factors (ESRP1,
CWC27, and DDX41). c Misregulation of splicing factors alternative splicing in HBV- (THBV/NNoV, yellow), HCV- (THCV/NNoV, blue), HBV&HCV-
(THBV&HCV/NNoV, green) and virus-free HCC (TNoV/NNoV, red). The delta PSI values are represented in red (negative delta PSI values) and in blue
(positive delta PSI values). d Expression levels of hnRNPC in patients with or without tumors (left panel). Kaplan–Meier overall survival curve (right
panel) for HCC patients expressing high (red) or low (blue) levels of hnRNPC. HNRNPC transcript level was negatively correlated with
overall survival
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We further investigated the implication of splicing fac-
tor levels on AS by using RNA interference and a re-
verse transcription-PCR screening platform to examine
the roles of splicing factors in different cell lines [23].
We selected various splicing factors which were over- or
under-expressed in HBV- and HCV-associated HCC.
These splicing factors were each targeted with specific
siRNAs, and we carried out a loss-of-function study in
various cell lines (PC-3, SKOV3, NIH:OVCAR-3, MDA-
MB-231, MCF7). In the case of HBV-associated HCC,
specific siRNAs were designed against splicing factors
U2AF2, SF3A2, RBM8A, RBM4, PRPF4B, NOVA1,
KHSRP, HNRPU, HNRPL, HNRPH1, HNRPC, and
HNRPA1. Depletion efficiencies were evaluated 96 h
posttransfection by Western blotting and/or quantitative
RT-PCR assays. All assays indicated that depletion had
been achieved (data not shown). We selected 96 tran-
scripts that belong to a subset of apoptotic genes be-
cause the functional consequences of alternative splicing
on apoptosis have previously been clearly established
[24]. Five of these transcripts (APP, AXIN1, F3, FGFR4,
and POLB) were of particular interest since their AS was
altered in HBV-associated HCC. The results are depicted
in Fig. 7 and show that the impact of the individual
knockdowns varies considerably. For instance, the
knockdown of SF3A2 has a definitive impact on the AS
pattern of the BCL2L1, C11ORF4, DRF1, FANCA,
FN1.3, POLB, PTPN13, SHC1, and TNFRSF10B tran-
scripts in all cell lines tested. However, the same knock-
down has no impact on the AS profile of numerous
transcripts such as BCMP11, CCL4, CTNNA1, FGFR1,
FGFR2, FN1.2, GAPD, GATA3, GNB3, HNRPAB,
HSC20, PAXIP1, PTK2, PTK2B, RAD52, RSN, SHMT1,
STM1, and TLK1 transcripts. We conclude that the ex-
pression of individual splicing factors has an impact on
AS profiles, but cannot explain all the changes observed.
The impact of the individual knockdowns on AS was
also analyzed for splicing factors which were over- or
under-expressed in HCV-associated HCC (Additional
file 1: Figure S6). As observed previously [23], our re-
sults demonstrate that targets for individual RNA spli-
cing factors can vary in different cellular contexts.
Expression pattern of hnRNPC significantly correlates with
patient survival
We next investigated the relationship between the
mRNA expression levels of proteins involved in RNA
splicing and patient survival. A substantial number of
HCC biomarkers with potential prognostic significance
have been identified in recent decades and have shown
Fig. 7 Modifications to AS of 96 transcripts in response to knockdown of splicing factors with specific siRNAs. Using specific siRNAs, twelve
splicing factors (U2AF2, SF3A2, RBM8A, RBM4, PRPF4B, NOVA1, KHSRP, HNRPU, HNRPL, HNRPH1, HNRPC, and HNRPA1) were individually knocked-
down in different cell lines to assess their implication in splicing of 96 differents transcripts. Individual knockdowns and ASEs are shown to indicate
which knockdowns caused a shift in alternative splicing in various cell lines (PC-3, SKOV3, NIH:OVCAR-3, MDA-MB-231, MCF7). Each column represents
a distinct knockdown performed with specific siRNAs. The changes in PSI values are displayed. The map depicts the changes in PSI values in a color-
coded scale. White areas indicate no shifts. Asterisks indicate transcripts for which AS was altered in HBV-associated HCC
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promising results [25]. Kaplan-Meier analysis was per-
formed to evaluate overall survival for patients as a func-
tion of the mRNA expression levels of proteins involved
in splicing. Of all the proteins involved in splicing for
which the expression level was modulated by more than
2-fold in HCC, the expression level of hnRNPC, a regula-
tor of mRNA splicing, was the only one showing correl-
ation with patient survival (Fig. 6d). A high level of
expression of hnRNPC was associated with reduced pa-
tient survival (p < 0.02 by Cox regression assay). No sig-
nificant correlations were found between high-levels of
hnRNPC expression and clinicopathological features, in-
cluding age, gender, and tumor stage. Interestingly, the
previous depletion assays (Fig. 7) indicated that a decrease
in hnRNP C expression affected 20 % (19/96) of the ASEs
tested in at least two cell lines, thereby demonstrating the
importance of this protein in the regulation of AS.
Expression of HBx alters cellular AS
Although changes in splicing patterns are features of can-
cer development/progression, it whether these changes
are the source or the consequence of a malignant pheno-
type remains unknown. We therefore investigated the at-
tractive possibility that the presence of a viral protein
could contribute to modifications in AS of virus-
associated HCC. We focused on the HBx protein of HBV
since currently available evidence supports a role for this
protein in the pathogenesis of HBV-associated HCC. HBx
has been shown to promote cell cycle progression, deacti-
vate negative growth regulators, and prevent the expres-
sion of tumor suppressor genes and senescence-related
factors [26]. The HBx protein (harboring a HA epitope)
was expressed in HEK293T cells and detected by SDS-
PAGE followed with anti-HA immunoblotting (Fig. 8a).
HEK293T cells were chosen because of their high trans-
fection efficiency and their extensive use in RNA splicing
studies [27–30]. We next relied on a high-throughput re-
verse transcription-PCR (RT-PCR)-based platform for
splicing annotation, to examine AS in 1200 cancer-
associated genes [31]. Once again, the relative abundance
of ASEs was expressed as PSI values. Our results demon-
strated that the AS patterns of 56 cancer-related genes
C D
Fig. 8 Involvement of the HBx protein from HBV in AS. a Immunoblotting analysis using anti-HA antibody for the detection of HBx-HA protein
from the cell lysates isolated after 5 days of transfection with pLenti6V5A-HBx. Control untransfected cells (T(−)) were also used in this assay. b List
of ASEs common to HBV-associated HCC and HBx-expressing cells. c Example of an ASE modified following the expression of HBx. Overview of
the two isoforms encoded by ENO3 gene. Exons are depicted in red and the intervening introns are shown as thin black lines (not to scale). The
primers used to detect the isoforms by RT-PCR assays are shown in gray and the sizes of the expected amplicons are also indicated (top panel).
RT-PCR reactions were performed on control cells (T(−)) and cells expressing HBx (HBx) using specific primers to detect both isoforms of the
transcripts encoded by the ENO3 gene. Capillary electrophoresis was performed and an image of the detected reaction products is shown (lower
panel). The positions of the expected amplicons are indicated by arrows. d Mass spectrometry analysis of cellular proteins interacting with HBx.
The average H/L ratios of the HBx affinity purification-mass spectrometry experiments were plotted versus the total intensities. The red dots
indicate cellular proteins involved in RNA splicing
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which were modified in HBV-associated HCC were also
significantly modified upon HBx expression (Fig. 8b). An
example of modified AS pattern modified upon HBx ex-
pression is provided in Fig. 8c.
The observation that the expression of HBx leads to
modifications in the AS profile of cellular genes led us
to investigate the ability of HBx to interact with cellular
proteins involved in splicing. We used a quantitative
proteomics-based approach relying on stable isotope la-
beling of amino acids in cell culture (SILAC) coupled to
mass spectrometry (LC-MS/MS) to identify cellular pro-
teins that interact with HBx. We used SILAC based on
three different sets of conditions in order to detect cellu-
lar proteins that bind to HBx in the absence of RNA/
DNA (see Methods). Cell lysates were incubated with
anti-HA antibodies and bound proteins were precipi-
tated, washed, eluted, trypsinized, and subjected to MS/
MS. Potential contaminants and non-specific binders
were considered using the CRAPOME database (Con-
taminant Repository for Affinity Purification and Mass
Spectrometry) [32]. Using such a strategy, our quantita-
tive mass spectrometry analysis demonstrated that SF1,
a splicing factor which is necessary in the early phases of
spliceosome assembly, was highly associated with HBx
(Fig. 8d). No other cellular protein involved in RNA spli-
cing was strongly associated with HBx. The role of this
interaction in the regulation of AS in HBV-associated
HCC will need to be further investigated in future
studies.
Discussion
In the current study, we present the first large-scale
screen of HCC–associated ASEs. The study demon-
strated that the AS patterns of numerous cellular tran-
scripts are modified in HCC. Moreover, these data
allowed us to identify unique signatures of genes for
which AS is misregulated in the different types of HCC.
Analysis of the AS landscape of the various types of
HCC revealed numerous potential HCC–specific
markers, which significantly increases the number of
biomarkers that can presently be identified by current
expression profiling approaches. We believe that our
study could lead to the identification of molecular candi-
dates for diagnostics and/or targetable pathways in
HCC. Currently, α-fetoprotein (AFP) together with path-
ology and iconography detection are routinely used in
early clinical diagnosis for liver cancer [33]. However,
the widely used marker AFP does not always yield satis-
factory results in the early diagnosis of HCC, particularly
in the case of AFP-negative HCC, thereby limiting the
universality of its application [33]. The use of other
HCC markers (such as GPC3 and TGF-β1) is presently
being explored [34], which is expected to improve early
diagnostic rate. Undoubtedly, future developments in
molecular genetics and proteomic analysis should lead
to the identification of other useful HCC-specific
markers. The current identification of unique signatures
for genes in which AS is misregulated in the different
types of HCC constitutes a step toward that goal.
In order to meet the augmented requirements of pro-
liferation, cancer cells frequently display important
changes in pathways of energy metabolism and nutrient
uptake [35]. Oncogenic transformation often results in
an increase in both bioenergetic potential and the nutri-
ent uptake in a cell-autonomous fashion [36]. The fact
that metabolic enzymes such as succinate dehydrogenase
(SDH) and fumarase (FH) function as tumor suppressors
in human cells suggests that metabolic dysregulation can
be an initiating event in cancer [36]. The recent discov-
ery of activating mutations in isocitrate dehydrogenase
(IDH1) in glioblastoma demonstrates that an activating
mutation in a metabolic enzyme are selected during car-
cinogenesis [37]. The emergence of metabolic enzymes
acting as important regulators of cancer cell growth
highly suggests that metabolic control is a critical factor
in carcinogenesis. In the present study, many transcripts
that were differentially spliced in HCC samples are
known to play critical roles in cell metabolism. For ex-
ample, the expression of the full-length ALDH2 tran-
script was found to be significantly reduced and
replaced by a shorter form that is predicted to encode a
truncated Aldh2 protein with a loss of a portion of the
aldehyde dehydrogenase domain. Aldehyde dehydrogen-
ase is a key enzyme involved in the major oxidative
pathway of alcohol metabolism. Interestingly, the en-
larged exposure to acetaldehyde in patients with a cata-
lytically inactive form of Aldh2 has previously been
shown to confer an increase susceptibility to many types
of cancer, including esophageal cancer [38]. Another ex-
ample of a gene involved in metabolism for which AS is
modified in HCC is HADHA, which encodes the alpha
subunit of the mitochondrial trifunctional protein cata-
lyzing the 3-hydroxyacyl-CoA dehydrogenase and enoyl-
CoA hydratase activities. These steps are involved in
mitochondrial beta-oxidation of long chain fatty acids.
Our results showed that the expression of the full-length
HADHA transcript was found to be significantly re-
duced and replaced by a shorter form that is predicted
to encode a truncated Hadha protein with a loss of a
portion of the enoyl-CoA domain. Interestingly, a link
between HADHA and cancer has previously been ob-
served in breast cancer where the HADHA gene was sig-
nificantly under-expressed in cancerous tissues, especially
in tumors with estrogen receptor-negative status [39].
In comparison with normal tissues, a substantial num-
ber of RNA splicing factors have been found to be up-
regulated or downregulated in various cancers. As
changes in the concentration of these factors have been
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shown to modify the selection of splice sites [40], it is pre-
dicted that the abnormally expressed splicing factors
found in cancerous cells induce the production of mRNA
isoforms that are either nonexistent or less abundant in
normal cells. A major challenge will be to determine if
these modifications contribute directly to carcinogenesis,
or whether they constitute one of the many processes that
are modified in cancer cells. The demonstration that over-
expression of the Serine/Arginine-Rich Splicing Factor 1
(SRSF1, also known as SF2/ASF) can trigger malignant
transformation suggests that the abnormal expression of
proteins involved in splicing can contribute to carcinogen-
esis [41]. In addition, the expression SRSF1 has been
shown to be increased in several tumor types [42] and fi-
broblasts overexpressing SRSF1 caused tumor formation
when injected into mice [41]. In the current study, many
changes in the expression levels and/or splicing patterns
of splicing factors were detected in HCC samples. Inter-
estingly, our data demonstrated that the transcript
encoded by ESRP1 was found to be significantly over-
expressed in all types of HCC investigated (32-fold
increase in HBV-associated HCC). How the altered ex-
pression dynamics of ESRP1 (and other splicing regula-
tors) contribute to AS homeostasis remains to be
examined. Interestingly, a previous report identified ASEs
regulated by Esrp1 using RNA silencing technology in a
human epithelial cell line [43]. Using such a strategy, the
authors identified 148 alternative splicing events in a total
of 134 different genes that were regulated by Esrp1 [43].
In the present study, the splicing of 32 of these Esrp1-
regulated transcripts are also found to be differentially
spliced in HBV-associated HCC suggesting, at least in
part, that some of the observed splicing alterations ob-
served in HCC could be related to Esrp1 over-expression.
In the case of HCV-associated HCC and virus-free HCC,
the splicing of 17 and 20 of these Esrp1-regulated tran-
scripts were also found to be differentially spliced,
respectively.
AS has been shown to add an additional layer of regula-
tion that functions in concert with transcriptional alter-
ations during the epithelial-to-mesenchymal transition
(EMT) [43]. EMT is an important and reversible process
during the development/differentiation of multiple organs
and has been implicated in cancer progression and me-
tastasis [44]. It involves reorganization of the actin cyto-
skeleton, loss of cell–cell adhesion, the acquisition of
increased cell motility, and changes in the transcriptional
profile of epithelial cells (such as downregulation of E-
cadherin and upregulation of vimentin and N-cadherin
[45]. Moreover, previous studies have shown that a down-
regulation of epithelial-specific splicing regulators (ESRP1
and ESRP2) occurs in cells which undergo EMT [46].
Down-regulation of ESRP1 and ESRP2 has also been
closely associated with a motile phenotype of cancer cells
[47]. EMT is a crucial event in HCC progression which
causes an increase in malignancy of hepatocytes associ-
ated with tumor cell invasion and metastasis [48]. For
HCC, intrahepatic metastasis is most frequent as the hep-
atic microenvironment displays a dense vasculature and is
the competent milieu for HCC cells in the metastasis cas-
cade [48]. In the current study, expression of ESRP1 was
significantly increased in HCC as evidenced from both
RNA-Seq and immunohistochemical analyses. This find-
ing was unexpected since downregulation of epithelial-
specific splicing regulators is usually associated with cells
undergoing EMT [46]. The exact significance of this result
is not understood at the moment. In HCC, EMT likely oc-
curs at the leading edge of tumor tissues under the par-
ticular control of extrinsic factors derived from the tumor
microenvironment in a paracrine fashion [46]. As such,
EMT is traditionally associated with highly metastatic
HCC. Moreover, it should be noted that both the epithelial
and mesenchymal cell phenotypes are not static. Indeed,
both cell types have the capacity to undergo important
cellular transformations (such as EMT and MET:
mesenchymal-to-epithelial transition) that can alter both
cellular morphology and behavior [43]. The MET-EMT
cycle, along with differences between primary HCC and
metastatic HCC, might also explain why no significant
evidence for gene over-expression of traditional mesen-
chymal markers (such as vimentin or N-cadherin) or re-
pression of epithelial ones (e.g., E-cadherin) was found in
tissues from HCC patients in the TCGA database.
Tumor markers based on the expression of specific
proteins that can be used in the prognosis of HCC have
been identified during the past few years, although con-
sensus has still not been reached [25]. More recently, an
important number of profiles based on the expression
levels of mRNAs have been used as predictors of prog-
nosis in various cancers [49]. For instance, the mRNAs
levels of hnRNP K, a member of the hnRNP family of
proteins which are involved in transcription, RNA spli-
cing, and translation, has previously been shown to be
aberrantly increased in numerous cancers [50, 51]. It
was reported that high-level hnRNP K expression is cor-
related with poorer overall survival among patients with
nasopharyngeal carcinoma (NPC) and prostate cancer
[50, 51]. High levels of expression of another member of
the family, namely hnRNP D, has also been linked to re-
duced survival in oral cancer [52]. In the current study,
a high level of mRNA expression of hnRNPC was also
associated with reduced patient survival in HCC. Clearly,
additional studies will need to be performed to see if
such an observation can eventually have any clinical ap-
plication. Nonetheless, validation of potential tumor
markers such as hnRNPC will continue to be a major
focus of HCC research in the next few years. Indeed, im-
provements in early diagnosis are still needed since only
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30 % of patients with HCC are candidates for potentially
curative treatments at the time of diagnosis [53]. We be-
lieve that some RNA splicing isoforms markers could
eventually be used as biomarkers. Ultimately, these
could serve as diagnostic or prognostic tool by detecting
their presence in cancer cells or in the fluids of patients.
Large-scale studies are starting to reveal the extent of
modifications that occur in AS in different types of can-
cer [14]. Although the precise mechanism which leads
to a modification of the AS landscape in HCC is un-
known at the moment, we demonstrated that the ex-
pression of the HBV HBx protein can result in
modifications in the AS profiles of cellular genes. Our
results showed that the AS patterns of 56 cancer-related
genes which were modified in HBV-associated HCC
were also significantly altered upon HBx expression,
thereby suggesting a potential mechanism by which a
viral infection can alter cellular AS profiles. Many direct
and/or indirect molecular mechanisms by which the ex-
pression of a viral protein such as HBx can lead to a
modification of the cellular AS landscape can be envis-
aged. However, the demonstration that HBx can interact
with splicing factor SF1 is clearly a step towards identify-
ing the steps required for the extensive modifications of
AS observed in HCC. Interestingly, strategies to modu-
late AS by splice-switching oligonucleotides in order to
correct aberrant ASEs, and/or to induce expression of
therapeutic splice variants are now being developed [17,
54]. It is tempting to speculate that such a strategy could
be applied to HCC. The current identification of exten-
sive changes in the cellular AS landscape in HCC likely
represents a first step toward the development of antic-
ancerous agents based on the AS modifications identi-
fied in HCC. The development of highly specific
molecular tools, such as splice-switching oligonucleo-
tides, which could precisely alter the proportion of splice
variants will also be critical to assess the function of
these splice variants.
Conclusions
The present analysis provided a comprehensive portrait
of global changes in the RNA splicing signatures that
occur in HCC. These data also allowed the identification
of unique signatures of genes for which AS is misregu-
lated in different types of HCC which could lead to the
identification of new molecular candidates for diagnos-
tics and/or targetable pathways in HCC.
Methods
RNA-seq data analysis
RNA-Seq samples were provided by the CGHub data
portal (https://cghub.ucsc.edu/). As only BAM files were
available at the time the data was obtained, a custom
script was used to extract read information from the
given alignment files and generate valid FASTQ files for
re-alignment (two FASTQ files with the reads in the
same order such that the aligner can align them in
pairs). Sequence reads were aligned on a transcriptome
reference sequence database (UCSCGene Hg19 using
Bowtie v2 aligner (default parameters) and associated
gene isoforms quantified in transcript-per-million (TPM)
using RSEM for each sequenced sample [55]. Alternative
splicing events were automatically detected and quantified
using the percent-spliced-in (PSI, Ψ) metric based on iso-
form expression TPM for the long (L) and the short (S)
forms using equation below:
Ψ ¼ L
L þ S
Genes with one single isoform or no Human Genome
Organisation (HUGO) ID were not considered for fur-
ther analysis.
Ethics, consent, and permissions
Not applicable. RNA-Seq data were obtained from the
TCGA Portal (https://tcga-data.nci.nih.gov/tcga/).
Gene expression analysis
The gene list was initially filtered to keep only data
present in at least two replicates for both virus-
associated HCC and normal hepatic tissue. The amount
of transcript in each sample was calculated in transcripts
per million (TPM) from the transcript-estimated read
counts which were provided by TCGA and the isoform
lengths from the UCSC (June 2011) annotation. To en-
sure higher reproducibility, only genes with expression
levels higher than one TPM in either dataset were con-
served. Fold changes in base 2 logarithm were then cal-
culated between both virus-associated HCC and normal
hepatic tissue average TPM. Q-values were calculated to
take into account multiple statistical hypothesis testing
and results under 0.05 were considered significant.
Alternative splicing analysis
The alternative splicing event (ASE) list was filtered to
keep only data present in at least two replicates for both
virus-associated HCC and normal hepatic tissue. Events
with a P-value less than 0.05 were conserved. To ensure
higher stringency, the ASEs were further filtered with a
cutoff Q-value of less than 0.05. From these events, only
those with a difference greater than 10 % in PSI were
considered biologically relevant.
Statistical analysis
Welch’s t-test (Student’s t-test with unequal sample sizes
and unequal variances) was calculated through the GSL
library (http://www.gnu.org/software/gsl/) integrated to
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Perl system analysis for gene expression and alternative
splicing data. Also, false discovery rates were calculated
with the Q-value package in R (https://cran.r-project.org/
src/contrib/Archive/qvalue/) based on Storey and Tibshirani
[56]. For all other analyses, Graph Pad Prism version 6.05
was used to run statistical analysis.
Gene ontology analysis
Gene ontology analysis with PANTHER was performed
using the database for annotation, visualization, and in-
tegrated discovery (DAVID) [57].
String networks
Using the STRING database (version 10) [58], genes
were submitted for generation of protein-protein inter-
action network from the Homo sapiens interactome.
High-resolution evidence views were created and saved.
Functional ASE prediction
Using the FAST-BD or EASANA suite, the splicing pat-
terns of genes of interest were visualized. DNA se-
quences of representative transcripts presenting short
and long isoforms were downloaded and translated into
proteins using ExPASy translation tool [59]. Predicted
proteins were then compared using Multalin (truncation
and frameshift event) [60], PFAM (loss or appearance of
a functional domain) [61], and NLS Mapper (loss or gain
of nuclear localization signal) [62].
PCR validation
Liver Cancer cDNA Arrays form Origene TissueScan
plates (Rockville, MD) were assessed for the expression
of the various transcripts using the manufacturer’s
protocol. The plates contained cDNAs from 8 normal
and 39 liver cancer tissues. All forward and reverse
primers were individually resuspended to 20–100 μM in
Tris-EDTA buffer (IDT) and diluted as a primer pair to
1 μM in RNase DNase-free water (IDT). PCR reactions
were performed in 10 μl in 96 well plates on a CFX-96
thermocycler (BioRad). The following cycling conditions
were used: 3 min at 95 °C; 50 cycles: 15 s at 95 °C, 30 s
at 60 °C, 30 s at 72 °C. For every PCR run, control reac-
tions performed in the absence of template were per-
formed for each primer pair and these were consistently
negative. The amplified products were analyzed by auto-
mated chip-based microcapillary electrophoresis on Cali-
per LC-90 instruments (Caliper LifeSciences). Amplicon
sizing and relative quantitation were performed by the
manufacturer’s software.
Splicing factors knockdown
siRNAs, Western blot analysis, RT-PCR assays and
bioinformatic analysis were performed as described
before [23].
Immunoprecipitation and mass spectrometry
HEK293T cells were grown in light (DMEM-R0K0),
medium (DMEM-R6K4) or heavy media (DMEM-R10K8)
containing the heavy isotopes of arginine and lysine sup-
plemented with 10 % fetal bovine serum. Cells were trans-
fected with pLenti6V5A-HBx to express the HBV HBx
protein for five days. Untransfected control cells were also
grown for 5 days. Cells were harvested separately, washed
three times with PBS, and treated (heavy) or not (light and
medium) with 20 mg/ml RNase A (Invitrogen) and 200
units DNase RQ1 (Promega) for two hours. Immunopre-
cipitation was performed using HA beads (Roche
11815016001) following the manufacturer’s instructions.
LC-MS/MS was performed as described previously [63].
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